M. Keskinkilic Et Al. , "Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?," Frontiers in oncology , vol.14, pp.1378563, 2024
Keskinkilic, M. Et Al. 2024. Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?. Frontiers in oncology , vol.14 , 1378563.
Keskinkilic, M., Semiz, H. S., Yavuzsen, T., & Oztop, I., (2024). Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?. Frontiers in oncology , vol.14, 1378563.
Keskinkilic, Merve Et Al. "Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?," Frontiers in oncology , vol.14, 1378563, 2024
Keskinkilic, Merve Et Al. "Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?." Frontiers in oncology , vol.14, pp.1378563, 2024
Keskinkilic, M. Et Al. (2024) . "Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?." Frontiers in oncology , vol.14, p.1378563.
@article{article, author={Merve Keskinkilic Et Al. }, title={Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?}, journal={Frontiers in oncology}, year=2024, pages={1378563} }